Eric Frings's Contact Details

Eric Frings's Company Details

Dynavax GmbH

Düsseldorf, North Rhine-Westphalia, Germany • 60 Employees
Research

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and Europe for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing its CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis, and universal influenza.Dynavax GmbH is the European affiliate of Dynavax Technologies Corporation USA, located in Düsseldorf, Germany. For more than 25 years, we have been dedicated to the development and manufacturing of vaccines and biopharmaceuticals.Dynavax GmbH is led by an experienced management team with demonstrated expertise in vaccine and biopharmaceutical product development and manufacturing. Our success is seen through the production of recombinant proteins of our licensed technology platform.As a center of excellence for commercial production we manufacture the drug substance for Heplisav B. The vaccine received approval by the US FDA in late 2017 and was approved in Europe in February 2021.Dynavax GmbH Employee Benefits- Jobrad- Recognition Awards- Fitness Membership- Flexible Working Hours- Free Membership for Corporate Benefits- Employee Breakfasts- Christmas and Summer Parties- Free Parking